
Compass Pathways completed its NDA for COMP360 based on 2 phase 3 trials and a phase 2b study with more than 1000 participants with highly chronic TRD.
Merrideth Leggat, MD, reviews clinical and practical implications of findings from the TRANSFORM and SUSTAIN studies exploring the utility of esketamine in the treatment of TRD.